These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10637399)

  • 1. Prevalence and correlates of parkinsonism in an institutionalized population of geriatric patients with chronic schizophrenia.
    Byne W; Stamu C; White L; Parrella M; Harvey PD; Davis KL
    Int J Geriatr Psychiatry; 2000 Jan; 15(1):7-13. PubMed ID: 10637399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment.
    Byne W; White L; Parella M; Adams R; Harvey PD; Davis KL
    Int J Geriatr Psychiatry; 1998 Jul; 13(7):473-9. PubMed ID: 9695037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinsonian signs in subjects with mild cognitive impairment.
    Boyle PA; Wilson RS; Aggarwal NT; Arvanitakis Z; Kelly J; Bienias JL; Bennett DA
    Neurology; 2005 Dec; 65(12):1901-6. PubMed ID: 16380610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease.
    Davidson M; Harvey P; Welsh KA; Powchik P; Putnam KM; Mohs RC
    Am J Psychiatry; 1996 Oct; 153(10):1274-9. PubMed ID: 8831434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extrapyramidal symptoms in unmedicated schizophrenia.
    McCreadie RG; Srinivasan TN; Padmavati R; Thara R
    J Psychiatr Res; 2005 May; 39(3):261-6. PubMed ID: 15725424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites.
    Harvey PD; Howanitz E; Parrella M; White L; Davidson M; Mohs RC; Hoblyn J; Davis KL
    Am J Psychiatry; 1998 Aug; 155(8):1080-6. PubMed ID: 9699697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of topography on the cognitive and psychopathological effects of tardive dyskinesia.
    Brown KW; White T
    Am J Psychiatry; 1992 Oct; 149(10):1385-9. PubMed ID: 1356314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mild parkinsonian signs and psycho-behavioral symptoms in subjects with mild cognitive impairment.
    Rozzini L; Chilovi BV; Bertoletti E; Conti M; Delrio I; Trabucchi M; Padovani A
    Int Psychogeriatr; 2008 Feb; 20(1):86-95. PubMed ID: 17868495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of spontaneous Parkinsonism in drug-naive patients with nonaffective psychotic disorders.
    Peralta V; Basterra V; Campos MS; de Jalón EG; Moreno-Izco L; Cuesta MJ
    Eur Arch Psychiatry Clin Neurosci; 2012 Mar; 262(2):131-8. PubMed ID: 21626260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severity of symptoms in chronically institutionalized geriatric schizophrenic patients.
    Davidson M; Harvey PD; Powchik P; Parrella M; White L; Knobler HY; Losonczy MF; Keefe RS; Katz S; Frecska E
    Am J Psychiatry; 1995 Feb; 152(2):197-207. PubMed ID: 7840352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study.
    Harvey PD; Lombardi J; Leibman M; White L; Parrella M; Powchik P; Davidson M
    Schizophr Res; 1996 Dec; 22(3):223-31. PubMed ID: 9000319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropsychological and functional correlates of clock-drawing test in elderly institutionalized patients with schizophrenia.
    Okamura A; Kitabayashi Y; Kohigashi M; Shibata K; Ishida T; Narumoto J; Morioka C; Kitabayashi M; Kashima A; Tani N; Nakaaki S; Mimura M; Fukui K
    Psychogeriatrics; 2012 Dec; 12(4):242-7. PubMed ID: 23279146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrapyramidal symptoms and cognitive test performance in patients with schizophrenia.
    Fervaha G; Agid O; Takeuchi H; Lee J; Foussias G; Zakzanis KK; Graff-Guerrero A; Remington G
    Schizophr Res; 2015 Feb; 161(2-3):351-6. PubMed ID: 25471015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinsonism in neuroleptic-naive schizophrenic patients.
    Caligiuri MP; Lohr JB; Jeste DV
    Am J Psychiatry; 1993 Sep; 150(9):1343-8. PubMed ID: 8352344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures.
    Yuen O; Caligiuri MP; Williams R; Dickson RA
    Br J Psychiatry; 1996 Jun; 168(6):702-8. PubMed ID: 8773812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tardive dyskinesia--diagnostic issues, subsyndromes, and concurrent movement disorders: a study of state hospital inpatients referred to a movement disorder consultation service.
    Lauterbach EC; Carter WG; Rathke KM; Thomas BH; Shillcutt SD; Vogel RL; Moore NC; Mimbs JW; Nelson WH
    Schizophr Bull; 2001; 27(4):601-13. PubMed ID: 11824487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors, pre-morbid functioning and episode correlates of neurological soft signs in drug-naive patients with schizophrenia-spectrum disorders.
    Peralta V; de Jalón EG; Campos MS; Basterra V; Sanchez-Torres A; Cuesta MJ
    Psychol Med; 2011 Jun; 41(6):1279-89. PubMed ID: 20860873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognition impairment in schizophrenia patients with tardive dyskinesia: association with plasma superoxide dismutase activity.
    Wu JQ; Chen DC; Tan YL; Tan SP; Wang ZR; Xiu MH; Yang FD; Zhang XY
    Schizophr Res; 2014 Jan; 152(1):210-6. PubMed ID: 24325977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Community dysfunction in schizophrenia: rate-limiting factors.
    Bozikas VP; Kosmidis MH; Kafantari A; Gamvrula K; Vasiliadou E; Petrikis P; Fokas K; Karavatos A
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):463-70. PubMed ID: 16442195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.